Literature DB >> 33925961

Highly Branched Polymers Based on Poly(amino acid)s for Biomedical Application.

Marisa Thompson1, Carmen Scholz1.   

Abstract

Polymers consisting of n>an class="Chemical">amino acid building blocks continue to receive consideration for biomedical applications. Since poly(amino acid)s are built from natural amino acids, the same building blocks proteins are made of, they are biocompatible, biodegradable and their degradation products are metabolizable. Some amino acids display a unique asymmetrical AB2 structure, which facilitates their ability to form branched structures. This review compares the three forms of highly branched polymeric structures: structurally highly organized dendrimers, dendrigrafts and the less organized, but readily synthesizable hyperbranched polymers. Their syntheses are reviewed and compared, methods of synthesis modulations are considered and variations on their traditional syntheses are shown. The potential use of highly branched polymers in the realm of biomedical applications is discussed, specifically their applications as delivery vehicles for genes and drugs and their use as antiviral compounds. Of the twenty essential amino acids, L-lysine, L-glutamic acid, and L-aspartic acid are asymmetrical AB2 molecules, but the bulk of the research into highly branched poly(amino acid)s has focused on the polycationic poly(L-lysine) with a lesser extent on poly(L-glutamic acid). Hence, the majority of potential applications lies in delivery systems for nucleic acids and this review examines and compares how these three types of highly branched polymers function as non-viral gene delivery vectors. When considering drug delivery systems, the small size of these highly branched polymers is advantageous for the delivery of inhalable drug. Even though highly branched polymers, in particular dendrimers, have been studied for more than 40 years for the delivery of genes and drugs, they have not translated in large scale into the clinic except for promising antiviral applications that have been commercialized.

Entities:  

Keywords:  antiviral; dendrigraft; dendrimer; drug delivery; gene delivery; hyperbranched polymer; poly(amino acid)

Year:  2021        PMID: 33925961     DOI: 10.3390/nano11051119

Source DB:  PubMed          Journal:  Nanomaterials (Basel)        ISSN: 2079-4991            Impact factor:   5.076


  91 in total

1.  In vitro gene transfection using dendritic poly(L-lysine).

Authors:  Mio Ohsaki; Tatsuya Okuda; Akihiro Wada; Toshiya Hirayama; Takuro Niidome; Haruhiko Aoyagi
Journal:  Bioconjug Chem       Date:  2002 May-Jun       Impact factor: 4.774

2.  Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent.

Authors:  Gemma M Ryan; Lisa M Kaminskas; Brian D Kelly; David J Owen; Michelle P McIntosh; Christopher J H Porter
Journal:  Mol Pharm       Date:  2013-06-26       Impact factor: 4.939

3.  Tumor-Associated Fibroblast-Targeted Regulation and Deep Tumor Delivery of Chemotherapeutic Drugs with a Multifunctional Size-Switchable Nanoparticle.

Authors:  Xingli Cun; Jiantao Chen; Mengmeng Li; Xuan He; Xian Tang; Rong Guo; Miao Deng; Man Li; Zhirong Zhang; Qin He
Journal:  ACS Appl Mater Interfaces       Date:  2019-10-16       Impact factor: 9.229

4.  Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity.

Authors:  Maarten Danial; Angela N Stauffer; Frederik R Wurm; Michael J Root; Harm-Anton Klok
Journal:  Bioconjug Chem       Date:  2016-10-27       Impact factor: 4.774

5.  Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses.

Authors:  Edwin Gong; Barry Matthews; Tom McCarthy; Jianhua Chu; George Holan; John Raff; Stephen Sacks
Journal:  Antiviral Res       Date:  2005-09-27       Impact factor: 5.970

6.  New method of polypeptide synthesis.

Authors:  M Mutter; H Hagenmaier; E Bayer
Journal:  Angew Chem Int Ed Engl       Date:  1971-11       Impact factor: 15.336

Review 7.  Everything You Always Wanted to Know about Poly-l-lysine Dendrigrafts (But Were Afraid to Ask).

Authors:  Jean-Patrick Francoia; Laurent Vial
Journal:  Chemistry       Date:  2018-01-17       Impact factor: 5.236

8.  Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker.

Authors:  Lisa M Kaminskas; Brian D Kelly; Victoria M McLeod; Gian Sberna; David J Owen; Ben J Boyd; Christopher J H Porter
Journal:  J Control Release       Date:  2011-02-21       Impact factor: 9.776

9.  Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.

Authors:  Lisa M Kaminskas; Brian D Kelly; Victoria M McLeod; Ben J Boyd; Guy Y Krippner; Elizabeth D Williams; Christopher J H Porter
Journal:  Mol Pharm       Date:  2009 Jul-Aug       Impact factor: 4.939

10.  Poly(lysine) Dendrimers Form Complexes with siRNA and Provide Its Efficient Uptake by Myeloid Cells: Model Studies for Therapeutic Nucleic Acid Delivery.

Authors:  Michał Gorzkiewicz; Olga Kopeć; Anna Janaszewska; Małgorzata Konopka; Elżbieta Pędziwiatr-Werbicka; Irina I Tarasenko; Valeriy V Bezrodnyi; Igor M Neelov; Barbara Klajnert-Maculewicz
Journal:  Int J Mol Sci       Date:  2020-04-29       Impact factor: 5.923

View more
  3 in total

Review 1.  Advances in the polymeric delivery of nucleic acid vaccines.

Authors:  Gang Chen; Bowen Zhao; Elena F Ruiz; Fuwu Zhang
Journal:  Theranostics       Date:  2022-05-13       Impact factor: 11.600

2.  Development of Multifunctional Nanoparticles for Therapy and/or Diagnosis.

Authors:  Sandrine Cammas-Marion
Journal:  Nanomaterials (Basel)       Date:  2022-07-06       Impact factor: 5.719

3.  New Fmoc-Amino Acids/Peptides-Based Supramolecular Gels Obtained through Co-Assembly Process: Preparation and Characterization.

Authors:  Alexandra Croitoriu; Loredana Elena Nita; Alina Gabriela Rusu; Alina Ghilan; Maria Bercea; Aurica P Chiriac
Journal:  Polymers (Basel)       Date:  2022-08-17       Impact factor: 4.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.